AU1396700A - Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases - Google Patents

Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases

Info

Publication number
AU1396700A
AU1396700A AU13967/00A AU1396700A AU1396700A AU 1396700 A AU1396700 A AU 1396700A AU 13967/00 A AU13967/00 A AU 13967/00A AU 1396700 A AU1396700 A AU 1396700A AU 1396700 A AU1396700 A AU 1396700A
Authority
AU
Australia
Prior art keywords
factor
polymorphism
diagnosis
treatment
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13967/00A
Inventor
Rakesh Anand
John Edward Norris Morten
John Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of AU1396700A publication Critical patent/AU1396700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU13967/00A 1998-12-05 1999-11-30 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases Abandoned AU1396700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9826747 1998-12-05
GBGB9826747.9A GB9826747D0 (en) 1998-12-05 1998-12-05 Chemical compounds
PCT/GB1999/003973 WO2000034515A1 (en) 1998-12-05 1999-11-30 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases

Publications (1)

Publication Number Publication Date
AU1396700A true AU1396700A (en) 2000-06-26

Family

ID=10843696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13967/00A Abandoned AU1396700A (en) 1998-12-05 1999-11-30 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases

Country Status (5)

Country Link
EP (1) EP1135534A1 (en)
JP (1) JP2002531144A (en)
AU (1) AU1396700A (en)
GB (1) GB9826747D0 (en)
WO (1) WO2000034515A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405517B (en) * 1997-02-27 1999-09-27 Immuno Ag FACTOR X-DELETION MUTANTS AND ANALOGS OF THEM

Also Published As

Publication number Publication date
WO2000034515A1 (en) 2000-06-15
GB9826747D0 (en) 1999-01-27
JP2002531144A (en) 2002-09-24
EP1135534A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
AU775126C (en) Substituted oxazolidinones and their use in the field of blood coagulation
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU5526399A (en) Improvements in or relating to the treatment of lesions
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
HK1068885A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n--
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
HUP0201997A3 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU1396700A (en) Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU2115197A (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU2003240253A1 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AU5875599A (en) Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases
AU5876399A (en) Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2713797A (en) Depigmentating agent in the treatment of melasma
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB0113011D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
GB0205963D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase